Two-year Phase III data presented at ASRS 2024 show Susvimo’ s potential as an alternative to eye injections to treat diabetic macular edema and ... Roche Global Media RelationsPhone: +41 61 688 ...

Basel, 04 February 2025- Roche announced today that the US Food and Drug Administration has approved Susvimo ® 100 mg/mL for the treatment of diabetic macular edema, a leading cause of vision ...

Roche RHHBY announced today that the FDA has approved a label expansion of ophthalmology drug Susvimo (ranibizumab injection). The regulatory body approved the drug Susvimo for the treatment of ...

First-of-Its-Kind Diabetic Retinopathy Treatment Approved Roche’s Susvimo is now the first and only FDA-approved continuous drug delivery system for diabetic retinopathy, requiring just one refill ...

Roche said that the Food and Drug Administration's decision was based on positive one-year results from the phase III of the Pagoda randomized study, which showed that Susvimo led to sustained ...

The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant to treat diabetic macular edema (DME). 1 In clinical trials, patients with DME who ...

Roche said its Susvimo drug received approval from the U.S. drug regulator for the treatment of diabetic retinopathy, a potentially blinding condition. Susvimo can help people with diabetic ...

F. Hoffmann-La Roche Ltd. Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic ...

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)With as few as two treatments per year ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...